Teleflex Incorporated (TFX)
NYSE • Healthcare
October 22, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Teleflex Incorporated keeps $18 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 29
in 7 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Teleflex Inc. beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported on Aug. 6, with adjusted EPS of $1.76 topping the $1.28 estimate by 37.5% and revenue of about $570.3 million edging the $559.6 million consensus by 1.9%. Revenue fell 27% from $780.9 million a year earlier, while adjusted EPS was down 52.8% from $3.73. Gross profit came to about $331.7 million, leaving gross margin near 58%, and operating income was about $60.3 million with operating margin about 11%. Operating cash flow was $95.9 million, and Teleflex repurchased about $245.4 million of stock and paid $14.8 million in dividends. For the next period, consensus calls for EPS of $1.82 on revenue of $580.8 million.
Next report — what to expect
Teleflex Inc (TFX) is set to report earnings on November 5, 2026. Wall Street’s next-period consensus calls for EPS of $1.90 on revenue of $565.4 million. For trailing context, revenue fell -27.0% year over year last quarter. Teleflex has beaten EPS in 7 of 8 most recent quarters.
About Teleflex Incorporated
Teleflex Incorporated is a healthcare company listed on the NYSE under TFX that designs, develops, manufactures, and distributes single-use medical devices for diagnostic and therapeutic procedures, especially in critical care and surgical settings. Across its medical instruments and supplies portfolio, Teleflex generated $2.0 billion of revenue in FY2025.
Today's Snapshot
TFX closed 4.8% above yesterday's close, in line with a firmer sector. Teleflex won Breakthrough Device status for Freesolve, a scaffold designed to dissolve after treatment. Earnings are due from TFX on 29 October.
Trading Volume
Below 10d avg (631.8K)
611.6K
vs S&P 500 Today
Strong Outperformance
+6.05%
Updated: October 22, 2026 at 20:12 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$125.17 - $129.69Buy
- RSI (14)66.97Neutral
- Stochastic %K (14, 3, 3)90.59Sell
- MACD Level (12, 26)0.72Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.